Soleus Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Soleus Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-42,400	Closed	-$2.38M	–	100
2023 Q2	$2.38M	Buy	+42,400	New	+$2.41M	0.26%	70
2023 Q1	–	Sell	-22,000	Closed	-$894K	–	80
2022 Q4	$894K	Hold	22,000	–	–	0.13%	65
2022 Q3	$1.44M	Hold	22,000	–	–	0.2%	63
2022 Q2	$1.34M	Hold	22,000	–	–	0.21%	64
2022 Q1	$1.38M	Hold	22,000	–	–	0.18%	61
2021 Q4	$1.67M	Sell	22,000 -70,214	-76%	-$6.13M	0.17%	57
2021 Q3	$10.3M	Sell	92,214 -10,900	-11%	-$1.37M	1.61%	18
2021 Q2	$16.7M	Buy	+103,114	New	+$12.5M	2.57%	10
2021 Q1	–	Sell	-10,825	Closed	-$1.66M	–	76
2020 Q4	$1.66M	Buy	10,825 +625	+6%	+$73.9K	0.22%	44
2020 Q3	$853K	Sell	10,200 -7,000	-41%	-$621K	0.45%	48
2020 Q2	$1.26M	Buy	17,200 +800	+5%	+$46.8K	0.72%	34
2020 Q1	$696K	Sell	16,400 -5,900	-26%	-$305K	0.81%	29
2019 Q4	$1.36M	Buy	+22,300	New	+$1.22M	1.31%	25

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Soleus Capital Management's CRSP Position: Q3 2023 in Review

Soleus Capital Management sold out of CRISPR Therapeutics (CRSP) in Q3 2023, closing a stake of 42,400 shares — an estimated $2.38M sold.

Soleus Capital Management first reported a position in CRSP in Q4 2019 and held it in 13 quarters. The position peaked at $16.7M in Q2 2021. 406 funds tracked by Wall St. Rank hold CRSP as of Q3 2023.

Soleus Capital Management reported no remaining CRISPR Therapeutics position as of Q3 2023 after selling out during the quarter.
Soleus Capital Management sold 42,400 CRISPR Therapeutics shares in Q3 2023, an estimated $2.38M.
Soleus Capital Management first reported a position in CRISPR Therapeutics in Q4 2019 and held it in 13 quarters.
Soleus Capital Management's CRISPR Therapeutics position peaked at $16.7M in Q2 2021.
406 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2023.

Based on Soleus Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.